肿瘤热休克蛋白-抗原肽复合物疫苗的临床研究  

Clinical researches on heat shock protein-peptide complex vaccines for cancer

作　　者：尹俊杰（综述）[1] 史斌（审校）[1] 

机构地区：[1]首都医科大学附属复兴医院血液内科,100038

出　　处：《国际肿瘤学杂志》2007年第6期411-413,共3页Journal of International Oncology

摘　　要：热休克蛋白．抗原肽复合物（HSPPC）被称为个体化肿瘤疫苗。临床研究显示HSPPC用于肿瘤患者免疫接种是安全可行的，它能触发部分患者强有力的抗肿瘤免疫排斥反应，并产生一定临床效果。研究发现临床效果与免疫学反应间有一定相关性，且不良反应轻微，未观察到自身免疫现象。The heat shock protein-peptide complex （HSPPC） is recognized as a personalized tumor vaccine. Some clinical trials completed in certain tumors show the vaccination with autologous tumor-derived HSPPC is a feasible and safe approach, and able to induce an strong antitumor response in a percentage of patients associated with clinical benefits. Clinical benefits are related with the antitumor response. No obvious toxicity and autoimmunity diseases related with the vaccination are observed.

关 键 词：热休克蛋白 癌症疫苗 生物治疗 

分 类 号：R730.51[医药卫生—肿瘤]